Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02173210 · ClinicalTrials.gov registry record
Precision Medicine for Preterm Birth
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 380
- Enrollment target
NCT02173210: Completed study, sponsored by University of Pennsylvania.
NCT02173210 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 380 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02173210 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 380 participants
- Enrollment target
Study Summary
This project is examining genetic and metabolic markers for the use of 17 hydroxyprogesterone caproate (17OHPC) in pregnant women with a history of preterm birth (PTB). 17OHPC has been associated with a 30-35% reduction in repeat PTB in women carrying a singleton gestation. However, it is not well known why it works for some women but not for others. There are limited available interventions for the prevention of recurrent PTB. This study will enroll 150 women at risk for PTB and eligible to receive 17OHPC, and expect that 80% will use 17OHPC and 20% will decline use. We will obtain blood samples and samples of cervical cells and cervical vaginal fluid. The objective of the study is to identify genetic, microbial and molecular markers that help to identify which women at risk for recurrent preterm birth will respond to 17OHPC and which women will not. The ultimate goal is to develop a personalized screening test based on these markers.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2014-06-25 |
| Est. Completion | 2017-12-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02173210
The ClinicalTrials.gov registry entry for NCT02173210 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02173210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02173210 about?
NCT02173210 is a clinical study titled "Precision Medicine for Preterm Birth". This project is examining genetic and metabolic markers for the use of 17 hydroxyprogesterone caproate (17OHPC) in pregnant women with a history of preterm birth (PTB). 17OHPC has been associated with a 30-35% reduction in repeat PTB in women carrying a singleton gestation. However, it is not well k...
What is the current status of trial NCT02173210?
This trial is currently completed. The enrollment target is 380 participants. The study started on 2014-06-25. Estimated completion is 2017-12-27.
Who is sponsoring clinical trial NCT02173210?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.